Literature DB >> 18021008

Association of bone morphogenetic proteins with otosclerosis.

Isabelle Schrauwen1, Melissa Thys, Kathleen Vanderstraeten, Erik Fransen, Nele Dieltjens, Jeroen R Huyghe, Megan Ealy, Mireille Claustres, Cor R W J Cremers, Ingeborg Dhooge, Frank Declau, Paul Van de Heyning, Robert Vincent, Thomas Somers, Erwin Offeciers, Richard J H Smith, Guy Van Camp.   

Abstract

UNLABELLED: We studied the role of polymorphisms in 13 candidate genes on the risk of otosclerosis in two large independent case-control sets. We found significant association in both populations with BMP2 and BMP4, implicating these two genes in the pathogenesis of this disease.
INTRODUCTION: Otosclerosis is a progressive disorder of the human temporal bone that leads to conductive hearing loss and in some cases sensorineural or mixed hearing loss. In a few families, it segregates as a monogenic disease with reduced penetrance, but in most patients, otosclerosis is more appropriately considered a complex disorder influenced by genetic and environmental factors.
MATERIALS AND METHODS: To identify major genetic factors in otosclerosis, we used a candidate gene approach to study two large independent case-control sets of Belgian-Dutch and French origin. Tag single nucleotide polymorphisms (SNPs) in 13 candidate susceptibility genes were studied in a stepwise strategy.
RESULTS: Two SNPs were identified that showed the same significant effect in both populations. The first SNP, rs3178250, is located in the 3' untranslated region of BMP2. Individuals homozygote for the C allele are protected against otosclerosis (combined populations: p = 2.2 x 10(-4); OR = 2.027; 95% CI = 1.380-2.979). The second SNP, rs17563, is an amino acid changing (p.Ala152Val) SNP located in BMP4. The G allele, coding for the amino acid alanine, confers susceptibility in both populations (combined populations: p = 0.002; OR = 1.209; 95% CI: 1.070-1.370).
CONCLUSIONS: These results indicate that polymorphisms in the BMP2 and BMP4 genes, both members of the TGF-beta superfamily, contribute to the susceptibility to otosclerosis and further strengthen the results from the recently reported association of TGFB1 with this disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18021008      PMCID: PMC2669162          DOI: 10.1359/jbmr.071112

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  76 in total

1.  Role of BMP-2a in otic capsule chondrogenesis.

Authors:  D A Frenz; W Liu; M Capparelli
Journal:  Ann N Y Acad Sci       Date:  1996-06-08       Impact factor: 5.691

Review 2.  Histopathology of otosclerosis.

Authors:  F H Linthicum
Journal:  Otolaryngol Clin North Am       Date:  1993-06       Impact factor: 3.346

3.  The human CD46 molecule is a receptor for measles virus (Edmonston strain).

Authors:  R E Dörig; A Marcil; A Chopra; C D Richardson
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

4.  A duplication/paracentric inversion associated with familial X-linked deafness (DFN3) suggests the presence of a regulatory element more than 400 kb upstream of the POU3F4 gene.

Authors:  Y J de Kok; G F Merkx; S M van der Maarel; I Huber; S Malcolm; H H Ropers; F P Cremers
Journal:  Hum Mol Genet       Date:  1995-11       Impact factor: 6.150

5.  The diastrophic dysplasia gene encodes a novel sulfate transporter: positional cloning by fine-structure linkage disequilibrium mapping.

Authors:  J Hästbacka; A de la Chapelle; M M Mahtani; G Clines; M P Reeve-Daly; M Daly; B A Hamilton; K Kusumi; B Trivedi; A Weaver
Journal:  Cell       Date:  1994-09-23       Impact factor: 41.582

6.  Age-related hearing loss and bone mass in a population of rural women aged 60 to 85 years.

Authors:  K Clark; M R Sowers; R B Wallace; M L Jannausch; J Lemke; C V Anderson
Journal:  Ann Epidemiol       Date:  1995-01       Impact factor: 3.797

7.  Association between X-linked mixed deafness and mutations in the POU domain gene POU3F4.

Authors:  Y J de Kok; S M van der Maarel; M Bitner-Glindzicz; I Huber; A P Monaco; S Malcolm; M E Pembrey; H H Ropers; F P Cremers
Journal:  Science       Date:  1995-02-03       Impact factor: 47.728

8.  Recombinant human bone morphogenetic protein-2 enhances expression of interleukin-6 and transforming growth factor-beta 1 genes in normal human osteoblast-like cells.

Authors:  M H Zheng; D J Wood; S Wysocki; J M Papadimitriou; E A Wang
Journal:  J Cell Physiol       Date:  1994-04       Impact factor: 6.384

9.  Effects of transforming growth factor beta on bone nodule formation and expression of bone morphogenetic protein 2, osteocalcin, osteopontin, alkaline phosphatase, and type I collagen mRNA in long-term cultures of fetal rat calvarial osteoblasts.

Authors:  S E Harris; L F Bonewald; M A Harris; M Sabatini; S Dallas; J Q Feng; N Ghosh-Choudhury; J Wozney; G R Mundy
Journal:  J Bone Miner Res       Date:  1994-06       Impact factor: 6.741

10.  Induction of chondrogenesis: requirement for synergistic interaction of basic fibroblast growth factor and transforming growth factor-beta.

Authors:  D A Frenz; W Liu; J D Williams; V Hatcher; V Galinovic-Schwartz; K C Flanders; T R Van de Water
Journal:  Development       Date:  1994-02       Impact factor: 6.868

View more
  25 in total

1.  Associations of polymorphisms in the bone morphogenetic protein-2 gene with risk and prognosis of osteosarcoma in a Chinese population.

Authors:  Yu Cong; Cheng-Jun Li; Jian-Ning Zhao; Xiao-Zhou Liu; Xin Shi
Journal:  Tumour Biol       Date:  2014-11-13

Review 2.  Etiopathogenesis of otosclerosis.

Authors:  Tamás Karosi; István Sziklai
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-06-09       Impact factor: 2.503

3.  Identification of target proteins involved in cochlear otosclerosis.

Authors:  Céline Richard; Joni K Doherty; Jose N Fayad; Ana Cordero; Fred H Linthicum
Journal:  Otol Neurotol       Date:  2015-06       Impact factor: 2.311

4.  Differences in gene expression between the otic capsule and other bones.

Authors:  Konstantina M Stankovic; Osamu Adachi; Kunikazu Tsuji; Arthur G Kristiansen; Joe C Adams; Vicki Rosen; Michael J McKenna
Journal:  Hear Res       Date:  2010-02-08       Impact factor: 3.208

5.  A genome-wide analysis identifies genetic variants in the RELN gene associated with otosclerosis.

Authors:  Isabelle Schrauwen; Megan Ealy; Matthew J Huentelman; Melissa Thys; Nils Homer; Kathleen Vanderstraeten; Erik Fransen; Jason J Corneveaux; David W Craig; Mireille Claustres; Cor W R J Cremers; Ingeborg Dhooge; Paul Van de Heyning; Robert Vincent; Erwin Offeciers; Richard J H Smith; Guy Van Camp
Journal:  Am J Hum Genet       Date:  2009-02-19       Impact factor: 11.025

Review 6.  Perspectives of pharmacological treatment in otosclerosis.

Authors:  Balázs Liktor; Zoltán Szekanecz; Tamás József Batta; István Sziklai; Tamás Karosi
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-07-29       Impact factor: 2.503

7.  Phenotype characterization and sequence analysis of BMP2 and BMP4 variants in two Mexican families with oligodontia.

Authors:  Y Mu; Z Xu; C I Contreras; J S McDaniel; K J Donly; S Chen
Journal:  Genet Mol Res       Date:  2012-11-28

Review 8.  An overview of the etiology of otosclerosis.

Authors:  Konstantinos Markou; John Goudakos
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-08-13       Impact factor: 2.503

9.  Exclusion of TNFRSF11B as Candidate Gene for Otosclerosis in Campania Population.

Authors:  Sandra Iossa; Giovanna Morello; Teresa Esposito; Virginia Corvino; Pasquale Giannini; Raffaella Salvato; Michele Cavaliere; Maria Panetti; Giuseppe Panetti; Bruno Piantedosi; Fernando Gianfrancesco; Elio Marciano; Annamaria Franzè
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2014-01-30

10.  Genetic variants in the RELN gene are associated with otosclerosis in multiple European populations.

Authors:  Isabelle Schrauwen; Megan Ealy; Erik Fransen; Kathleen Vanderstraeten; Melissa Thys; Nicole C Meyer; Marcel Cosgarea; Alex Huber; Manuela Mazzoli; Markus Pfister; Richard J H Smith; Guy Van Camp
Journal:  Hum Genet       Date:  2009-10-22       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.